FDA Approves Genentech’s WILSERDLY
The FDA has approved Genentech’s WILSERDLY (giredestrant), a next‑generation oral SERD, for the treatment of ER‑positive, ESR1‑mutated advanced breast cancer. In the Phase III evERA trial, WILSERDLY combined with everolimus significantly delayed disease progression or death by 62% compared with standard endocrine therapy plus everolimus in patients with ESR1 mutations. ESR1 mutations, detected by an FDA‑approved test, are a major cause of hormone‑therapy resistance in up to 40% of patients.